GlassScriptPhysician profile
Shreya Patel
NPI 1417462680
$11,440.32
in general payments reported to CMS, 2019-2025
52 companies · $4,226 in 2025
The $4,226 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $849 · 2023: $3,870 · 2024: $2,496 · 2025: $4,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,526.37 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.01 | 2022-2025 | |
| Pfizer INC. | $712.00 | 2023-2025 | |
| Biogen, INC. | $701.70 | 2022-2025 | Vumerity, Tysabri, Spinraza |
| Novartis Pharmaceuticals Corporation | $560.51 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $559.00 | 2023-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $513.39 | 2022-2025 | Hyqvia, Gammagard |
| Emd Serono, INC. | $503.93 | 2022-2025 | Mavenclad |
| Genentech USA, INC. | $489.43 | 2022-2025 | Ocrevus, Enspryng, Evrysdi |
| Argenx US, INC. | $484.03 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $471.76 | 2023-2025 | Zilbrysq, Briviact, Nayzilam |
| Genzyme Corporation | $456.94 | 2022-2025 | |
| Lilly USA, LLC | $423.71 | 2022-2025 | Amyvid, Emgality, Reyvow |
| Lundbeck LLC | $418.72 | 2022-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $382.68 | 2023-2025 | |
| Amgen INC. | $321.55 | 2022-2025 | Uplizna, Aimovig |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $273.80 | 2023-2024 | Nuedexta, Rexulti |
| Csl Behring | $273.46 | 2022-2025 | Hizentra, Andembry |
| Horizon Therapeutics Plc | $230.15 | 2022-2023 | Uplizna |
| Vanda Pharmaceuticals INC. | $214.15 | 2024-2025 | Ponvory |
| Banner Life Sciences, LLC | $205.56 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $201.95 | 2023-2025 | Horizant, Horizant |
| Neurocrine Biosciences, INC. | $197.58 | 2023-2025 | Ingrezza |
| Celgene Corporation | $139.24 | 2024-2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $127.07 | 2024-2025 | Acthar |
| Grifols USA, LLC | $112.69 | 2023-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $102.48 | 2024-2025 | Radicava |
| Acadia Pharmaceuticals INC | $97.27 | 2024-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $95.93 | 2023-2025 | Austedo Xr, Ajovy |
| Janssen Pharmaceuticals, INC | $89.48 | 2022-2023 | Ponvory |
| Merz Pharmaceuticals, LLC | $83.49 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Amylyx Pharmaceuticals, INC. | $70.06 | 2023-2024 | Relyvrio |
| Idorsia Pharmaceuticals US INC | $51.45 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $51.44 | 2022-2025 | Wainua |
| Biohaven Pharmaceutical Holding Company LTD. | $49.28 | 2022 | |
| Sandoz INC. | $47.71 | 2024 | |
| Acorda Therapeutics, INC | $46.03 | 2023-2024 | Ampyra |
| Eisai INC. | $42.00 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $39.97 | 2025 | |
| Avanir Pharmaceuticals, INC. | $37.73 | 2022 | |
| Boston Scientific Corporation | $29.88 | 2025 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $27.50 | 2022 | |
| Ani Pharmaceuticals, INC. | $26.84 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $24.71 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $22.60 | 2023 | |
| Arbor Pharmaceuticals, INC. | $22.43 | 2022 | |
| Neurelis, INC. | $21.86 | 2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $21.03 | 2023 | Lyvispah |
| Impel Pharmaceuticals INC. | $20.91 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $20.87 | 2023 | Givlaari |
| Cycle Pharmaceuticals INC | $18.35 | 2025 | Tascenso Odt |
| C2n Diagnostics, LLC | $17.04 | 2025 | Precivityad2 |
| Janssen Biotech, INC. | $15.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shreya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.